Altering AAV tropism with mosaic viral capsids
- PMID: 15922956
- DOI: 10.1016/j.ymthe.2005.03.005
Altering AAV tropism with mosaic viral capsids
Abstract
Over the past decade, AAV-based vectors have emerged as promising candidates for gene therapeutic applications. Despite the broad tropism of the first eight serotypes identified, certain cell types are refractory to transduction with AAV-based vectors. Furthermore, for certain applications the targeting of specific cell types is desirable. To improve on present methods to alter AAV2 tropism, we take advantage of AAV2 mosaics. Here, we show that AAV2 mosaics have improved infectivity compared with all-mutant virions. Using an AAV2 mutant that contains the immunoglobulin-binding Z34C fragment of protein A, we demonstrate the utility of AAV2 mosaics to alter AAV2 tropism. This system allows us to transduce selectively and efficiently MO7e and Jurkat cells. The use of AAV2 mosaics with a protein A fragment inserted into their capsid, together with targeting antibodies, is a versatile method that allows the specific transduction of a wide array of cell types.
Similar articles
-
Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.Mol Ther. 2001 Sep;4(3):174-81. doi: 10.1006/mthe.2001.0424. Mol Ther. 2001. PMID: 11545607
-
Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.Virology. 2004 Dec 20;330(2):375-83. doi: 10.1016/j.virol.2004.10.012. Virology. 2004. PMID: 15567432
-
Receptor targeting of adeno-associated virus vectors.Gene Ther. 2003 Jul;10(14):1142-51. doi: 10.1038/sj.gt.3301976. Gene Ther. 2003. PMID: 12833123 Review.
-
Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations.J Gene Med. 2009 Dec;11(12):1103-13. doi: 10.1002/jgm.1392. J Gene Med. 2009. PMID: 19777441
-
Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer.Pharm Res. 2008 Mar;25(3):489-99. doi: 10.1007/s11095-007-9431-0. Epub 2007 Sep 1. Pharm Res. 2008. PMID: 17763830 Free PMC article. Review.
Cited by
-
Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency.Gene Ther. 2023 Apr;30(3-4):236-244. doi: 10.1038/s41434-020-00198-7. Epub 2020 Oct 7. Gene Ther. 2023. PMID: 33028973 Free PMC article.
-
Adeno-associated virus vector as a platform for gene therapy delivery.Nat Rev Drug Discov. 2019 May;18(5):358-378. doi: 10.1038/s41573-019-0012-9. Nat Rev Drug Discov. 2019. PMID: 30710128 Free PMC article. Review.
-
Gene therapy in monogenic congenital myopathies.Methods. 2016 Apr 15;99:91-8. doi: 10.1016/j.ymeth.2015.10.004. Epub 2015 Oct 14. Methods. 2016. PMID: 26454198 Free PMC article. Review.
-
Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transduction.Virology. 2007 Oct 10;367(1):10-8. doi: 10.1016/j.virol.2007.05.009. Epub 2007 Jun 22. Virology. 2007. PMID: 17588632 Free PMC article.
-
AAV's anatomy: roadmap for optimizing vectors for translational success.Curr Gene Ther. 2010 Oct;10(5):319-340. doi: 10.2174/156652310793180706. Curr Gene Ther. 2010. PMID: 20712583 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous